Latest TLR8 Stories

2014-09-02 08:30:25

- Management Team, Funding, Immunotherapy Trials - SEATTLE, Sept. 2, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts....

2013-03-05 10:44:28

Promising compound may help protect babies during vulnerable window The underdeveloped immune systems of newborns don't respond to most vaccines, leaving them at high risk for infections like rotavirus, pertussis (whooping cough) and pneumococcus. Researchers at Boston Children's Hospital have identified a potent compound that activates immune responses in newborns' white blood cells substantially better than anything previously tested, and that could potentially make vaccines effective...

2008-10-16 09:00:43

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present preclinical data from studies on its autoimmune disease program at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society being held at the Harvard Medical School Conference Center in Boston, October 15-18, 2008. The Company's presentations describe studies of novel compounds targeted to Toll-like Receptors (TLRs), including the evaluation of TLR antagonist compounds in preclinical models of autoimmune...

Word of the Day
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.